Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jan;61(1):221-9.
doi: 10.1007/s10620-015-3866-7. Epub 2015 Nov 12.

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Gary R Lichtenstein  1 , Glenn L Gordon  2 , Salam Zakko  3 , Uma Murthy  4 , Shahriar Sedghi  5 , Ron Pruitt  6 , Andrew C Barrett  7 , Enoch Bortey  7 , Craig Paterson  7 , William P Forbes  7
Affiliations
Meta-Analysis

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Gary R Lichtenstein et al. Dig Dis Sci. 2016 Jan.

Abstract

Background: Patients with ulcerative colitis (UC) who achieve remission with corticosteroids often relapse after tapering or discontinuation; alternative treatments limiting steroid exposure and UC relapse would be beneficial. It remains uncertain whether patients with corticosteroid-induced remission experience benefit with mesalamine granules (MG), a locally acting aminosalicylate extended-release capsule formulation for maintenance of UC remission in adults.

Aims: Efficacy and safety of MG 1.5 g once daily was evaluated in patients with UC in corticosteroid-induced remission.

Methods: Data from patients with previous corticosteroid use to achieve baseline UC remission were analyzed from two 6-month randomized, double-blind, placebo-controlled trials and a 24-month open-label extension (OLE). Six-month relapse-free rates were assessed using the revised Sutherland Disease Activity Index. UC-related adverse events (AEs) were recorded during the 30 months.

Results: Included were 158 steroid-treated patients in UC remission (MG, n = 105; placebo, n = 53) and 74/105 MG-treated patients who continued MG in the OLE. A significantly larger percentage of patients remained relapse-free at 6 months with MG (77.1 %) versus placebo (54.7 %; P = 0.006), with a 55 % reduction in relapse risk (hazard ratio [HR] 0.45; 95 % CI 0.25-0.79). There was a similar (49.2 %) reduction in risk of UC-related AEs at 6 months (HR 0.51; 95 % CI 0.31-0.84; P = 0.009) that was sustained during the OLE.

Conclusions: MG 1.5 g once daily administered for maintenance of corticosteroid-induced remission was associated with low risk of relapse and UC-related AEs. CLINICALTRIALS.GOV: NCT00744016, NCT00767728, and NCT00326209.

Keywords: Inflammatory bowel diseases; Mesalamine; Remission; Steroids; Ulcerative colitis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition for subpopulation of patients previously treated with corticosteroids for induction or maintenance of remission of ulcerative colitis during the two double-blind Phase 3 trials (MPUC3003 and MPUC3004) and the open-label extension trial (MPUC3005). MG mesalamine granules, OLE open-label extension. aSafety data not available for 4 patients (3 in the MG group and 1 in the placebo group)
Fig. 2
Fig. 2
Probability of remaining relapse-free during 6 months of treatment in patients previously treated with corticosteroids (MPUC3003 and MPUC3004, pooled). P value determined using Poisson regression analysis. MG mesalamine granules
Fig. 3
Fig. 3
Probability of remaining free from ulcerative colitis (UC)-related adverse events (AEs; defined as UC, hematochezia, or frequent bowel movements) during short-term treatment (MPUC3003 and MPUC3004, pooled) and long-term treatment (MPUC3005). MG mesalamine granules
See this image and copyright information in PMC

References

    1. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76:1323–1330. - PubMed
    1. Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523. doi: 10.1038/ajg.2009.727. - DOI - PubMed
    1. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17:3204–3212. - PMC - PubMed
    1. Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517. doi: 10.1053/j.gastro.2004.01.063. - DOI - PubMed
    1. Everhart JE, Ed. The Burden of Digestive Diseases in the United States. Washington, DC: United States Department of Health and Human Services; Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008. http://www2.niddk.nih.gov/NR/rdonlyres/0B814CEA-222A-4677-9B38-89D3BC34E.... Accessed February 12, 2013. Report no. NIH Publication No. 09-6443.

Publication types

MeSH terms

Associated data